A number of questions remain unsettled about the release of melanocyte stimulating hormone (MSH) and about its function. Even though relatively few investigators are studying this area, some generalities have emerged during the last 10 yr. It now seems that release of MSH from the pituitary is inhibited by a substance present in the hypothalamus. The structure of this physiologic inhibitor of MSH release may still not be considered an established entity but there is evidence for additional mechanisms capable of exerting a fine control on the release of MSH. Contrary to some opinions, the release of MSH does not always occur together with the release of ACTH, and the release of the 2 hormones can be dissociated in several laboratory and clinical situations. In addition, many studies have shown that the pituitary peptide, MSH, exerts behavioral and electroencephalographic effects in both the rat and man. The hypothalamic peptide Pro Leu Gly NH2 (MIF I) also has direct effects on the central nervous system that may include alleviation of the symptoms of Parkinson's disease.
|Original language||English (US)|
|Number of pages||5|
|Journal||Mayo Clinic Proceedings|
|State||Published - Dec 1 1976|
ASJC Scopus subject areas